Morphosys
在场
Morphosys 是一家在股票代码 MPSYY (DE) 下上市的公司。
Morphosys 在 2 个国家有直接业务。
高管
查看带有其 22 名主要高管的组织结构图
Morphosys 搜索最多的简介
- Arkadius Pichota, Chief Executive Officer
- Silke Mainka, Director
- Romain Lege, Deputy Chairman of the Supervisory Board
高管在Morphosys变化
- Arkadius Pichota已作为Chief Executive Officer加入公司 (新闻发布的2024六月9号).
- George Golumbeski, Deputy Chairman, 已经离开公司 (新闻发布的2024六月9号).
- Lukas Gilgen已作为Chief Financial Officer加入公司 (新闻发布的2024六月9号).
创建提醒
跟踪 Morphosys 的高管变动
药店
Morphosys 拥有 1,840 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Grace Therapeutics将在Oct 25, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
- Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
药店 行业的其他推荐联系人
消息
Morphosys 的最新新闻稿
- Official partner of the Eurovision Song Contest 2025
- Novartis Financial Results – Q3 2024
- Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial
- Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior efficacy, and favorable safety and tolerability profile
- Events
- Novartis continues strong momentum in Q3 with 10% sales growth, 20% core operating income growth, and important innovation milestones; raises FY 2024 guidance
- Novartis ribociclib (Kisqali®) recognized as Category 1 preferred breast cancer adjuvant treatment by NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
- Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
- MorphoSys Completes Voluntary Delisting from the Frankfurt Stock Exchange and Nasdaq Global Market
- MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
- View more press releases Close
通过电子邮件
